The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases
Abstract
BACKGROUND: Expression of platelet-derived growth factor (PDGF) and activation (by autophosphorylation) of its receptor (PDGF-R), a tyrosine kinase, are associated with the growth of metastatic prostate tumor cells in the bone parenchyma. The tyrosine kinase inhibitor STI571 blocks the PDGF signaling pathway by inhibiting PDGF-R autophosphorylation. We examined the effects of STI571, given alone or with paclitaxel (Taxol), on tumor growth in a mouse model of prostate cancer metastasis. METHODS: Human prostate cancer PC-3MM2 cells were injected into the tibias of male nude mice. Three days later the mice (20 per group) were randomly assigned to 5 weeks of treatment with oral and injected water (control), daily oral STI571, weekly injected paclitaxel, or STI571 plus paclitaxel. Lesions in bone and the surrounding muscles were then harvested and analyzed by histology, western blotting (for PDGF-R phosphorylation), immunohistochemistry (for expression of proangiogenic molecules), and double immunofluorescence (to identify endothelial cells and apoptotic tumor cells). Growth of bone lesions was monitored by digital radiography. Bone lesions from control mice were used to establish short-term cell cultures for analysis of PDGF-R phosphorylation. All statistical tests were two-sided. RESULTS: PC-3MM2 cells cultured from bone lesions and treated in vitro with STI571 had less phosphorylated PDGF-R than untreated cells. In control mice, bone lesions expressed high levels of PDGF and activated (i.e., phosphorylated) PDGF-R, whereas lesions in the adjacent musculature did not. Activated PDGF-R was present on the surface of endothelial cells within the bone lesions but not in endothelial cells of uninjected bone. Mice treated with STI571 or STI571 plus paclitaxel had a lower tumor incidence, smaller tumors, and less bone lysis and lymph node metastasis than mice treated with water or paclitaxel alone (P<.001 for all). Mice treated with STI571 or STI571 plus paclitaxel had less phosphorylated PDGF-R on tumor cells and tumor-associated endothelial cells, less tumor cell proliferation, statistically significantly more apoptotic tumor cells (all P<.001), and fewer tumor-associated endothelial cells (P<.001) than control mice. CONCLUSIONS: Endothelial cells appear to express phosphorylated PDGF-R when they are exposed to tumor cells that express PDGF. Using STI571 to inhibit PDGF-R phosphorylation may, especially in combination with paclitaxel, produce substantial therapeutic effects against prostate cancer bone metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Matsubara, H., Moriguchi, Y., Mori, Y., Masaki, H., Tsutsumi, Y., Shibasaki, Y., Uchiyama‐Tanaka, Y., Fujiyama, S., Koyama, Y., Nose, A., et al. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4351-0_22 · Cited by 21
RetractedApplied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“95, No. 6, March 19, 2003 ARTICLES 467 proangiogenic factors other than PDGF, such as bFGF, IL-8, VEGF, IL-1, or TNF- ( 14 ,17,18).”
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,595
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
The biology of platelet-derived growth factor
Ross, R., Raines, E. W., & Bowen-Pope, D. F. (1986) · Cell · doi:10.1016/0092-8674(86)90733-6 · Cited by 2,008
GROWTH FACTOR RECEPTOR TYROSINE KINASES
Yarden, Y., & Ullrich, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002303 · Cited by 1,838
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Fidler, I. J. (1990) · PubMed · Cited by 1,278
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
The role of angiogenesis in tumor growth.
Folkman, J. (1992) · PubMed · Cited by 1,259
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055
Gerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60862-3 · Cited by 510
Morikawa, K., Walker, S. M., Nakajima, M., Pathak, S., Jessup, J. M., & Fidler, I. J. (1988) · PubMed · Cited by 474
Self-citationThe seed and soil hypothesis: vascularisation and brain metastases
Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00622-2 · Cited by 432
Self-citationBornfeldt, K. E., Raines, E. W., Nakano, T., Graves, L. M., Krebs, E. G., & Ross, R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117081 · Cited by 409
Pettaway, C. A., Pathak, S., Greene, G., Ramirez, E. I., Wilson, M. R., Killion, J. J., & Fidler, I. J. (1996) · PubMed · Cited by 408
Self-citationTashjian, A. H., Voelkel, E. F., Lazzaro, M., Singer, F. R., Roberts, A. B., Derynck, R., Winkler, M. E., & Levine, L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4535 · Cited by 380
Nistér, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson, L., Heldin, C., Schlessinger, J., & Westermark, B. (1988) · PubMed · Cited by 353
Angiogenesis inhibition: A review
Auerbach, W., & Auerbach, R. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90027-2 · Cited by 321
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T. W., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D. F., Fine, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.958 · Cited by 313
Spread of prostatic cancer to bone
Jacobs, S. C. (1983) · Urology · doi:10.1016/0090-4295(83)90147-4 · Cited by 286
Modulation of the Organ Microenvironment for Treatment of Cancer Metastasis
Fidler, I. J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.21.1588 · Cited by 240
Self-citationPlate, K. H., Breier, G., Farrell, C. L., & Risau, W. (1992) · PubMed · Cited by 219
Henriksen, R., Funa, K., Wilander, E., Bäckström, T., Ridderheim, M., & Öberg, K. (1993) · PubMed · Cited by 219
Spyridopoulos, I., Brogi, E., Kearney, M., Sullivan, A. B., Cetrulo, C., Isner, J. M., & Losordo, D. W. (1997) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0365 · Cited by 217
Rak, J., Filmus, J., & Kerbel, R. S. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00396-6 · Cited by 202
Baker, C. H., Solórzano, C. C., & Fidler, I. J. (2002) · PubMed · Cited by 196
Self-citationA role of PDGFRα in basal cell carcinoma proliferation
Xie, J., Aszterbaum, M., Zhang, X., Bonifas, J. M., Zachary, C., Epstein, E., & McCormick, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151173398 · Cited by 192
Nistér, M., Claesson-Welsh, L., Eriksson, A., Heldin, C. H., & Westermark, B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55365-5 · Cited by 178
Genetic Control of Cancer Metastasis
Fidler, I. J., & Radinsky, R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.3.166 · Cited by 175
Self-citationYi, B., Williams, P. J., Niewolna, M., Wang, Y., & Yoneda, T. (2002) · PubMed · Cited by 172
Chott, A., Sun, Z., Morganstern, D., Pan, J., Li, T., Susani, M., Mosberger, I., Upton, M. P., Bubley, G. J., & Balk, S. P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65229-7 · Cited by 161
Smith, D. C., Esper, P., Strawderman, M., Redman, B., & Pienta, K. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1664 · Cited by 159
Ko, Y. J., Small, E. J., Kabbinavar, F. F., Chachoua, A., Taneja, S. S., Reese, D., Depaoli, A., Hannah, A. L., Balk, S. P., & Bubley, G. J. (2001) · PubMed · Cited by 150
Endothelium-derived factors as paracrine mediators of prostate cancer progression
Pirtskhalaishvili, G., & Nelson, J. B. (2000) · The Prostate · Cited by 142
Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow.
Chackal-Roy, M., Niemeyer, C. M., Moore, M., & Zetter, B. R. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114167 · Cited by 141
Shawver, L. K., Schwartz, D. P., Mann, E., et al. (1997) · PubMed · Cited by 131
Antoniades, H. N., Galanopoulos, T., Neville-Golden, J., & O’Hara, C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3942 · Cited by 120
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 118
Self-citationSeymour, L., Dajee, D., & Bezwoda, W. R. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665802 · Cited by 102
Watanabe, Y., & Dvorak, H. F. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3583 · Cited by 96
Boerner, P., Resnick, R. J., & Racker, E. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.5.1350 · Cited by 93
Sitaras, N. M., Sariban, E., Bravo, M., Pantazis, P., & Antoniades, H. N. (1988) · PubMed · Cited by 93
Saha, D., Datta, P. K., Sheng, H., Morrow, J. D., Wada, M., Moses, H. L., & Beauchamp, R. D. (1999) · Neoplasia · doi:10.1038/sj.neo.7900051 · Cited by 84
Lindmark, G. E., Sundberg, C., Glimelius, B. L. G., et al. (1993) · PubMed · Cited by 82
Karsdal, M. A., Fjording, M. S., Foged, N. T., Delaissé, J.-M., & Lochter, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008738200 · Cited by 81
Fudge, K., Bostwick, D. G., & Stearns, M. E. (1996) · The Prostate · Cited by 80
Funa, N. S., Papanicolaou, V., Juhlin, C., Rastad, J., Åkerström, G., Heldin, C. H., & Öberg, K. (1990) · PubMed · Cited by 78
McCormick, F. P. (2001) · Nature · doi:10.1038/35085665 · Cited by 75
Wang, J., Coltrera, M. D., & Gown, A. M. (1994) · PubMed · Cited by 64
Yoon, S., Tefferi, A., & Li, C. (2000) · Acta Haematologica · doi:10.1159/000046507 · Cited by 59
Yoshida, K., Kuniyasu, H., Yasui, W., Kitadai, Y., Toge, T., & 田原, 榮. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01218421 · Cited by 56
Chung, C. K., & Antoniades, H. N. (1992) · PubMed · Cited by 49
Krasagakis, K., Garbe, C., & Orfanos, C. E. (1993) · PubMed · Cited by 30
Krasagakis, K., Garbe, C., & Orfanos, C. E. (1993) · Melanoma Research · doi:10.1097/00008390-199311000-00005 · Cited by 29
Soory, M., & Virdi, H. (1999) · Journal of Periodontology · doi:10.1902/jop.1999.70.10.1136 · Cited by 10
Beyond Pancreatic Cancer: Irinotecan and Gemcitabine in Solid Tumors and Hematologic Malignancies
Lima, C. M. S. R., Urbanic, J. J., Lal, A., Hall, R. K., Brunson, C. Y., & Green, M. R. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)80007-5 · Cited by 8
Cited by
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Self-citationAACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective
Talmadge, J. E., & Fidler, I. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1040 · Cited by 1,169
Self-citationScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Langley, R. R., & Fidler, I. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26031 · Cited by 958
Self-citationProgress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Metadata
- Authors
- Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., & Fidler, I. J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03-19
- Volume
- 95
- Issue
- 6
- Pages
- 458-470
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W1988698591
- Cited by
- 280
- References
- 71
- FWCI
- 26.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.